Apellis Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell APLS and other ETFs, options, and stocks.

About APLS

Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. Its products include EMPAVELI and SYFOVRE. 

CEO
Cedric Francois
CEOCedric Francois
Employees
710
Employees710
Headquarters
Waltham, Massachusetts
HeadquartersWaltham, Massachusetts
Founded
2009
Founded2009
Employees
710
Employees710

APLS Key Statistics

Market cap
2.52B
Market cap2.52B
Price-Earnings ratio
68.95
Price-Earnings ratio68.95
Dividend yield
Dividend yield
Average volume
3.98M
Average volume3.98M
High today
$20.64
High today$20.64
Low today
$19.93
Low today$19.93
Open price
$20.50
Open price$20.50
Volume
3.08M
Volume3.08M
52 Week high
$35.72
52 Week high$35.72
52 Week low
$16.10
52 Week low$16.10

Stock Snapshot

As of today, Apellis Pharmaceuticals(APLS) shares are valued at $19.93. The company's market cap stands at 2.52B, with a P/E ratio of 68.95.

On 2025-11-06, Apellis Pharmaceuticals(APLS) stock traded between a low of $19.93 and a high of $20.64. Shares are currently priced at $19.93, which is +0.0% above the low and -3.4% below the high.

Apellis Pharmaceuticals(APLS) shares are trading with a volume of 3.08M, against a daily average of 3.98M.

In the last year, Apellis Pharmaceuticals(APLS) shares hit a 52-week high of $35.72 and a 52-week low of $16.10.

In the last year, Apellis Pharmaceuticals(APLS) shares hit a 52-week high of $35.72 and a 52-week low of $16.10.

APLS News

TipRanks 9h
Hold Rating on Apellis Pharmaceuticals: Balancing Stagnant Revenue Growth and Market Challenges

Wolfe Research analyst Andy Chen has maintained their neutral stance on APLS stock, giving a Hold rating on November 3. Meet Your ETF AI Analyst Discover how Ti...

TipRanks 6d
Apellis Pharmaceuticals Reports Strong Q3 2025 Earnings

Apellis Pharmaceuticals ( (APLS) ) has released its Q3 earnings. Here is a breakdown of the information Apellis Pharmaceuticals presented to its investors. Elev...

Analyst ratings

60%

of 20 ratings
Buy
60%
Hold
35%
Sell
5%

People also own

Based on the portfolios of people who own APLS. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.